Alliance Pharma PLC Notification of Preliminary Results (0672R)
February 26 2019 - 2:02AM
UK Regulatory
TIDMAPH
RNS Number : 0672R
Alliance Pharma PLC
26 February 2019
26 February 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Notification of Preliminary Results
Alliance Pharma plc (AIM: APH), the international healthcare
group, will announce its preliminary results for the year ended 31
December 2018 on Tuesday 26 March 2019.
A briefing for analysts will be held at 11.00am on the morning
of the results at the offices of Buchanan, 107 Cheapside, London
EC2V 6DN.
To access a webcast of the analyst presentation, please log on
to the following web address several minutes before 11.00am on the
day of the results:
http://webcasting.buchanan.uk.com/broadcast/5c6e8e68e6e1d92d38f4f7e1
For more information, please contact Buchanan on 020 7466 5000
or email alliancepharma@buchanan.uk.com.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Michael Meade /
Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with affiliate offices in Europe,
the Far East and the US and wide international reach through an
extensive network of distributors, generating sales in more than
100 countries.
We currently own or license the rights to more than 90
pharmaceutical and consumer healthcare products, which are managed
on a portfolio basis according to their growth potential.
Promotional investment is focussed on a small number of brands with
significant international or multi-territory reach. The remainder
of the portfolio comprises products which are sold in a limited
number of local markets and require little or no promotional
investment.
Our tried and tested 'Buy and Build' strategy, allows us to
benefit both from organic growth opportunities and from enhancing
our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORDELFLKLFEBBB
(END) Dow Jones Newswires
February 26, 2019 02:02 ET (07:02 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024